Publication:
The inhibitory effect of liposome‐encapsulated indomethacin on inflammation and platelet aggregation

dc.contributor.authorsGürsoy A., Akbuğga J., Eroğglu L., Uluti̇N ş.
dc.date.accessioned2022-03-15T01:47:47Z
dc.date.accessioned2026-01-10T17:00:18Z
dc.date.available2022-03-15T01:47:47Z
dc.date.issued1988
dc.description.abstractAbstract— A comparison has been made between liposome‐encapsulated and free indomethacin for their anti‐inflammatory activities in the carrageenan paw oedema test in rats, and their inhibitory effect on platelet aggregation induced by adenosine 5‐diphosphate (ADP) in‐vitro. Free indomethacin, 3 mg kg−1, strongly inhibited carrageenan‐induced oedema and a similar inhibitory activity was shown by 0.3 mg kg−1 of encapsulated drug. For the inhibition of platelet aggregation, the threshold concentration of free drug was 0.559 mM. At this concentration, at least 5 min incubation was needed to achieve 12.5% and 45 min for 50% inhibition. The inhibition was much stronger with encapsulated drug, and pre‐incubation of 28 μM encapsulated drug for 10 min with platelet‐rich plasma before addition of ADP completely inhibited platelet aggregation. 1988 Royal Pharmaceutical Society of Great Britain
dc.identifier.doi10.1111/j.2042-7158.1988.tb05150.x
dc.identifier.issn223573
dc.identifier.pubmed2896775
dc.identifier.urihttps://hdl.handle.net/11424/246175
dc.language.isoeng
dc.relation.ispartofJournal of Pharmacy and Pharmacology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleThe inhibitory effect of liposome‐encapsulated indomethacin on inflammation and platelet aggregation
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage54
oaire.citation.issue1
oaire.citation.startPage53
oaire.citation.titleJournal of Pharmacy and Pharmacology
oaire.citation.volume40

Files